Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin versus vasopressin for bleeding reduction during laparoscopic myomectomy
IRCT20150817023666N15Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jul 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of oxytocin and vasopressin in Fibromyoma (LM) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Amount of blood loss during surgery. Started Jul 2022; status: completed.
02
Drugs
oxytocinvasopressin
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20150817023666N15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150817023666N15.